tert-butyl 4-(5-(2-fluoro-4-nitrophenoxy)-1-methyl-1H-indazol-6-yl)-1H-pyrazole-1-carboxylate | 1206800-42-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: tert-butyl 4-(5-(2-fluoro-4-nitrophenoxy)-1-methyl-1H-indazol-6-yl)-1H-pyrazole-1-carboxylate
• 英文别名: tert-butyl 4-[5-(2-fluoro-4-nitrophenoxy)-1-methylindazol-6-yl]pyrazole-1-carboxylate
• CAS: 1206800-42-1
• 化学式: C₂₂H₂₀FN₅O₅
• 分子量: 453.43
• InChiKey: BGENEXHSQIGPRB-UHFFFAOYSA-N

物化性质

• 沸点：
  580.4±60.0 °C(Predicted)
• 密度：
  1.40±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  33
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  117
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-(5-(2-fluoro-4-nitrophenoxy)-1-methyl-1H-indazol-6-yl)-1H-pyrazole-1-carboxylate 在 palladium 10% on activated carbon 、 氢气 、 1-羟基苯并三唑 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 20.0 ℃ 、344.75 kPa 条件下， 反应 78.0h， 生成 N-[3-氟-4-[[1-甲基-6-(1H-吡唑-4-基)-1H-吲唑-5-基]氧基]苯基]-1-(4-氟苯基)-1,2-二氢-6-甲基-2-氧代-3-吡啶甲酰胺
  参考文献：
  名称：

  Route Design and Development of a MET Kinase Inhibitor: A Copper-Catalyzed Preparation of an N1-Methylindazole

  摘要：

  The synthesis of a MET kinase inhibitor in an overall yield of 22% was achieved over eight steps starting with 3-hydroxybenzaldehyde, an improvement from the initial 12-step process with a 5.4% yield. Highlights of the process chemistry design and development are a Cu-catalyzed cyclization to form an important N1-methylindazole ring, a selective nitro reduction in the presence of an aryl bromide, a late-stage Suzuki cross-coupling, and a base-promoted Boc deprotection to form the desired drug candidate.

  DOI：

  10.1021/op400317z
• 作为产物：
  描述：

  2-甲基-4-甲氧基苯胺 在 盐酸 、 aluminum (III) chloride 、 potassium phosphate monohydrate 、 dichloro[1,1'-bis(di-t-butylphosphino)ferrocene]palladium(II) 、 二碳酸二叔丁酯 、 potassium tert-butylate 、 溴 、 碳酸氢钠 、 溶剂黄146 、 sodium nitrite 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 57.0h， 生成 tert-butyl 4-(5-(2-fluoro-4-nitrophenoxy)-1-methyl-1H-indazol-6-yl)-1H-pyrazole-1-carboxylate
  参考文献：
  名称：

  Route Design and Development of a MET Kinase Inhibitor: A Copper-Catalyzed Preparation of an N1-Methylindazole

  摘要：

  The synthesis of a MET kinase inhibitor in an overall yield of 22% was achieved over eight steps starting with 3-hydroxybenzaldehyde, an improvement from the initial 12-step process with a 5.4% yield. Highlights of the process chemistry design and development are a Cu-catalyzed cyclization to form an important N1-methylindazole ring, a selective nitro reduction in the presence of an aryl bromide, a late-stage Suzuki cross-coupling, and a base-promoted Boc deprotection to form the desired drug candidate.

  DOI：

  10.1021/op400317z

文献信息

• AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET
  申请人：LI Tiechao

  公开号：US20100022529A1

  公开（公告）日：2010-01-28

  The present invention provides amidophenoxyindazole compounds useful in the treatment of cancer.

  这项发明提供了在癌症治疗中有用的酰胺基苯氧基吲唑化合物。
• OXO-PYRIDINE FUSION RING DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
  申请人：Wellmarker Bio Co., Ltd.

  公开号：EP4011885A1

  公开（公告）日：2022-06-15

  An oxo-pyridine fusion ring derivative compound represented by chemical formula 1 or a pharmaceutically acceptable salt thereof according to the present invention effectively inhibits the activity of RON and can not only effectively suppress the cell growth of cancer cell lines in which RON is activated, but also can effectively kill the cancer cell lines. Therefore, the oxo-pyridine fusion ring derivative compound represented by chemical formula 1 or a pharmaceutically acceptable salt thereof according to the present invention can be advantageously used for preventing or treating a disease associated with protein kinase activity.

  根据本发明，化学式1所代表的一种氧代吡啶融合环衍生物化合物或其药学上可接受的盐，可以有效抑制RON的活性，不仅可以有效抑制RON被激活的癌细胞系的细胞生长，还可以有效杀死癌细胞系。因此，根据本发明，化学式1所代表的氧代吡啶融合环衍生物化合物或其药学上可接受的盐可以有利地用于预防或治疗与蛋白激酶活性相关的疾病。
• Amidophenoxyindazoles useful as inhibitors of c-Met
  申请人：Eli Lilly and Company

  公开号：US08030302B2

  公开（公告）日：2011-10-04

  The present invention provides amidophenoxyindazole compounds useful in the treatment of cancer.

  本发明提供了在癌症治疗中有用的酰胺基苯氧基吲唑化合物。
• COMPOUND HAVING AXL AND C-MET KINASE INHIBITORY ACTIVITY, PREPARATION THEREOF AND APPLICATION THEREOF
  申请人：Shanghai Institute of Materia Medica, Chinese Academy of Sciences

  公开号：EP4029862A1

  公开（公告）日：2022-07-20

  A compound having Axl and c-Met kinase inhibitory activity, a preparation method therefor and an application thereof. Specifically, a compound having the structure represented by formula (I), a preparation method therefor and an application thereof in the preparation of a medication for the treatment and/or prevention of tumor-associated diseases and/or kinase-related diseases.

  具有Axl和c-Met激酶抑制活性的化合物，其制备方法及其应用。具体来说，该化合物具有由式（I）表示的结构，其制备方法及其在制备用于治疗和/或预防与肿瘤相关的疾病和/或激酶相关疾病的药物中的应用。
• TRK INHIBITOR AS ANTI-CANCER DRUG
  申请人：Tyligand Bioscience (Shanghai) Limited

  公开号：EP3848365A1

  公开（公告）日：2021-07-14

  The present disclosure relates to a group of tropomyosin receptor kinase inhibitors comprising an amido-phenoxy-indazole structure fragment. These compounds show potent inhibitory effects on various oncogenic kinases, especially TRK, and thus can be used to treat tumors or cancers.

  本公开涉及一组肌球蛋白受体激酶抑制剂，包括氨基苯氧基吲唑结构片段。这些化合物对各种致癌激酶（尤其是 TRK）具有强效抑制作用，因此可用于治疗肿瘤或癌症。